Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review

Abstract Background Obesity and type 2 diabetes are the primary drivers of atherosclerotic cardiovascular disease (ASCVD), the leading cause of death worldwide. Injectable GLP-1 receptor agonists reduce major adverse cardiovascular events. Yet for many individuals, injection hesitancy remains a sign...

Descripció completa

Dades bibliogràfiques

Autors principals:	Adir Alper, Gal Peleg, Adina Fagin, Priyansh Shah, Ishmum Chowdhury, Antony Gonzales, Robert Faillace
Format:	Artigo
Idioma:	Inglês
Publicat:	BioMed Central 2026-02-01
Col·lecció:	Cardiovascular Diabetology. Endocrinology Reports
Matèries:	Orforglipron Oral GLP-1 receptor agonist Type 2 diabetes mellitus Cardiometabolic risk
Accés en línia:	https://doi.org/10.1186/s40842-025-00270-4
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!